Category: Press Releases

Intensity Therapeutics’ CEO, Lewis H. Bender, Named One of PharmaVOICE’s 100 Most Inspiring People for 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of the company’s proprietary therapeutic agents, today announced that the July/August issue of the publication PharmaVOICE has named Lewis H. Bender, the Company’s Founder, President and CEO, as one of its 100 most inspiring people… Read more »

Intensity Therapeutics’ INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of the company’s proprietary therapeutic agents, today announced the publication in the journal OncoImmunology of results from nonclinical research conducted in partnership with the National Cancer Institute’s (NCI) Vaccine Branch under a Cooperative Research and… Read more »

Intensity Therapeutics Announces Clinical Collaboration with Merck

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that it has entered into an agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Intensity’s lead… Read more »

Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO)… Read more »

Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that a poster highlighting the safety profile, tumor regression activity and immune activation of the company’s lead product candidate, INT230-6, will be presented at the American Society of… Read more »

Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that Lewis H. Bender, President and CEO, will present a poster on the preclinical and early Phase 1/2 data of its lead product candidate, INT230-6, at The New… Read more »

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed or… Read more »

Intensity Therapeutics Recognizes Rare Disease Day 2019

Intensity Therapeutics, Inc. joins patients, caregivers and rare disease advocates worldwide to recognize Rare Disease Day 2019, which is February 28. The main objective of the day is to raise public awareness of rare diseases, which are often severely debilitating illnesses that have a dramatic impact on patients’ lives. “Unfortunately, such diseases do not receive… Read more »

Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced that Lewis H. Bender, President and CEO, will participate in the “Reshaping Tumor Microenvironments via Immunotherapies” panel at the 2019 BIO CEO & Investor Conference. The panel will examine… Read more »

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced the receipt of patents protecting the Company’s technology and its lead product candidate, INT230-6, in China, Japan, Korea, Russia and Australia. All five countries have granted the Company a… Read more »